{
  "docId": "019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "docSlug": "87d7e2eb7c56e30923dbf29903df5034",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 40,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide illustrates the mechanism of action of CTX-009 as a bispecific antibody and compares the effects of single-agent anti-VEGF vs anti-DLL4 blockade.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-dee8-7497-a5f7-ae2745d7f9f6/7",
  "deckHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "deckJsonHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6.json",
  "deckAnchorHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.48,
        "x": 0.47,
        "y": 0.44
      },
      "kind": "callout",
      "text": "Dual blockade of DLL4 and VEGF overcomes VEGF resistance",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9a8ba88-9559-4f9f-890e-3422ccba7fa7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.48,
        "x": 0.47,
        "y": 0.55
      },
      "kind": "diagram",
      "text": "Comparison of Anti-VEGF vs Anti-DLL4 signaling pathways and tumor growth outcomes",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a76cef7-85de-4bf5-addc-97076b59528a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.6,
        "y": 0.05
      },
      "kind": "image",
      "text": "Antibody structure diagram showing binding to VEGF and DLL4",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c70cbf35-5e69-4d91-9ab9-441b84d3d19d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Bispecific antibody blocking DLL4 (Notch-1 ligand) and VEGF-A (soluble ligand)\nDoes not lead to ADCC, Fc inactive\nBinds to its targets with 2:2 valency\nAt 10 mg/Kg, CTX-009 has approximately the same VEGF-A capturing ability as bevacizumab (Avastin)\nThe only DLL4 X VEGF bispecific that demonstrated monotherapy activity in the clinic in colorectal and gastric cancer\nDurable responses in patients with cholangiocarcinoma seen in Phase 1b study of CTX-009 in combination with paclitaxel",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36d04dc0-66bd-46d6-a2af-a085ec4fc1cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "Overview of CTX-009",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ad07a9d-94ab-4a20-9127-1a03d52dcd22",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}